CNRS, Inserm, IPMC, Université Côte d'Azur, Valbonne, France.
CNRS, CHU Lille, Institut Pasteur de Lille, UMR 8199-EGID, Université Lille, 59000 Lille, France.
J Diabetes Res. 2016;2016:3142175. doi: 10.1155/2016/3142175. Epub 2016 Dec 25.
Inhibition of the potassium channels TREK-1 by spadin (SPA) is currently thought to be a promising therapeutic target for the treatment of depression. Since these channels are expressed in pancreatic -cells, we investigated their role in the control of insulin secretion and glucose homeostasis. In this study, we confirmed the expression of TREK-1 channels in the insulin secreting MIN6-B1 -cell line and in mouse islets. We found that their blockade by SPA potentiated insulin secretion induced by potassium chloride dependent membrane depolarization. Inhibition of TREK-1 by SPA induced a decrease of the resting membrane potential (Δ ~ 12 mV) and increased the cytosolic calcium concentration. In mice, administration of SPA enhanced the plasma insulin level stimulated by glucose, confirming its secretagogue effect observed in vitro. Taken together, this work identifies SPA as a novel potential pharmacological agent able to control insulin secretion and glucose homeostasis.
目前,认为通过 spadin(SPA)抑制钾通道 TREK-1 是治疗抑郁症的有希望的治疗靶点。由于这些通道在胰腺β细胞中表达,因此我们研究了它们在胰岛素分泌和葡萄糖稳态控制中的作用。在这项研究中,我们证实了 TREK-1 通道在胰岛素分泌的 MIN6-B1 细胞系和小鼠胰岛中的表达。我们发现,它们被 SPA 阻断可增强由钾氯离子依赖性膜去极化诱导的胰岛素分泌。SPA 抑制 TREK-1 会降低静息膜电位(Δ~12 mV)并增加细胞溶质钙浓度。在小鼠中,SPA 的给药增强了葡萄糖刺激的血浆胰岛素水平,证实了其在体外观察到的促分泌作用。总之,这项工作确定 SPA 是一种新型潜在的药理学药物,能够控制胰岛素分泌和葡萄糖稳态。